Keyword: Amneal Pharmaceuticals

At least three new emergency epinephrine marketers are challenging longtime market leader Mylan and its EpiPen.

Amneal CEO Chintu Patel expects to expand a plant in New York and add 400 employees as a merger with Impax nears.

Surprise, surprise: Impax Labs, looking to bulk up amid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal.

Impax Labs CEO Paul Bisaro, who has extensive experience building companies through M&A, is reportedly in talks with competitor Amneal.